These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10365591)

  • 21. Assessment of intravenous immunoglobulin non-responders in Kawasaki disease.
    Hwang JY; Lee KY; Rhim JW; Youn YS; Oh JH; Han JW; Lee JS; Burgner D
    Arch Dis Child; 2011 Nov; 96(11):1088-90. PubMed ID: 20551193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leukotriene B4 and Kawasaki disease.
    Hamasaki Y; Miyazaki S
    Acta Paediatr Jpn; 1991 Dec; 33(6):771-7. PubMed ID: 1666246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive factors of coronary aneurysm in Kawasaki disease--correlation between coronary arterial lesions and serum albumin, cholinesterase activity, prealbumin, retinol-binding protein and immature neutrophils.
    Nakano M
    Prog Clin Biol Res; 1987; 250():535-7. PubMed ID: 3423065
    [No Abstract]   [Full Text] [Related]  

  • 24. Brain natriuretic peptide levels in Kawasaki disease: a case report.
    Iwashima S; Ishikawa T; Ohzeki T
    Pediatr Int; 2009 Jun; 51(3):415-8. PubMed ID: 19500284
    [No Abstract]   [Full Text] [Related]  

  • 25. Granulocyte colony-stimulating factor ameliorates coronary artery elastin breakdown in a mouse model of Kawasaki disease.
    Liu J; Chen Z; Du Z; Lu D
    Chin Med J (Engl); 2014; 127(21):3712-7. PubMed ID: 25382324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma fibronectin concentrations in mucocutaneous lymph node syndrome.
    Shimizu S; Kuratsuji T; Ojima T; Takahashi E
    Arch Dis Child; 1986 Jan; 61(1):72-4. PubMed ID: 3954421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease.
    Senzaki H; Masutani S; Kobayashi J; Kobayashi T; Nakano H; Nagasaka H; Sasaki N; Asano H; Kyo S; Yokote Y
    Circulation; 2001 Aug; 104(8):860-3. PubMed ID: 11514369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of severe coronary sequelae of Kawasaki disease.
    Tatara K; Murata M; Itoh K; Kazuma N; Kondo C
    Am Heart J; 1996 Mar; 131(3):576-81. PubMed ID: 8604640
    [No Abstract]   [Full Text] [Related]  

  • 29. [The function of Th1/Th2 cells in children with acute Kawasaki disease].
    Chang J; Lu JR; Liang D
    Zhonghua Er Ke Za Zhi; 2006 May; 44(5):377-8. PubMed ID: 16780718
    [No Abstract]   [Full Text] [Related]  

  • 30. Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki Disease.
    Nishihara S; Ishibashi K; Iribe K; Matsuda I
    Lancet; 1988 Oct; 2(8617):973. PubMed ID: 2459575
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy and safety of immunoglobulin retreatment in Kawasaki disease.
    Falcini F; Ermini M; Trapani S; Taccetti G
    J Pediatr; 1994 Oct; 125(4):672-3. PubMed ID: 7931898
    [No Abstract]   [Full Text] [Related]  

  • 32. Coronary heart disease in children with Kawasaki disease.
    Kato H; Koike S; Tanaka C; Yokochi K; Yoshioka F; Takeuchi S; Matsunaga S; Yokoyama T
    Jpn Circ J; 1979 May; 43(5):469-75. PubMed ID: 470108
    [No Abstract]   [Full Text] [Related]  

  • 33. Hemophagocytosis complicating Kawasaki disease.
    al-Eid W; al-Jefri A; Bahabri S; al-Mayouf S
    Pediatr Hematol Oncol; 2000 Jun; 17(4):323-9. PubMed ID: 10845231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kawasaki disease: who is at risk?
    Newburger JW
    J Pediatr; 2000 Aug; 137(2):149-52. PubMed ID: 10931403
    [No Abstract]   [Full Text] [Related]  

  • 35. Fate of coronary arterial aneurysms in Kawasaki disease.
    Suzuki A; Kamiya T; Arakaki Y; Kinoshita Y; Kimura K
    Am J Cardiol; 1994 Oct; 74(8):822-4. PubMed ID: 7942561
    [No Abstract]   [Full Text] [Related]  

  • 36. Changes in BAFF/APRIL levels in a 2-year-old girl with Kawasaki disease refractory to intravenous immunoglobulin therapy.
    Yoshida S; Sakurai Y; Takeda T; Fukuda K
    J Investig Allergol Clin Immunol; 2013; 23(1):52-3. PubMed ID: 23653975
    [No Abstract]   [Full Text] [Related]  

  • 37. Serum-soluble interleukin-2 receptor levels in Kawasaki disease.
    Lang BA; Silverman ED; Laxer RM; Rose V; Nelson DL; Rubin LA
    J Pediatr; 1990 Apr; 116(4):592-6. PubMed ID: 2319407
    [No Abstract]   [Full Text] [Related]  

  • 38. Long-term issues in Kawasaki disease.
    Gersony WM
    J Pediatr; 1992 Nov; 121(5 Pt 1):731-3. PubMed ID: 1432422
    [No Abstract]   [Full Text] [Related]  

  • 39. [Current viewpoints in the pathogenesis of Kawasaki disease].
    Bollen CW; Rijkers GT; Zegers BJ; de Graeff-Meeder ER
    Ned Tijdschr Geneeskd; 1995 Mar; 139(11):549-54. PubMed ID: 7700390
    [No Abstract]   [Full Text] [Related]  

  • 40. Inverse correlation between macrophage-colony stimulating factor, cholesterol and high density lipoprotein cholesterol in Kawasaki disease.
    Shikishima Y; Kawano Y; Shirai H; Matsuura N; Noma T
    Asian Pac J Allergy Immunol; 2001 Jun; 19(2):85-91. PubMed ID: 11699725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.